Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bac-FRP-3
- Development stage
- Preclinical
- Lead developer
- iNtRON Biotechnology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Bac-FRP-3 is a lytic bacteriophage belonging to the *Siphoviridae* family that specifically targets and lyses enterotoxigenic *Bacteroides fragilis* (ETBF). Developed by iNtRON Biotechnology, Bac-FRP-3 is designed to selectively eliminate ETBF, a colorectal cancer (CRC)-associated pathobiont that disrupts epithelial tight junctions and promotes chronic inflammation. In preclinical studies using patient-derived normal colon organoids, treatment with Bac-FRP-3 restored epithelial viability, preserved E-cadherin expression, reduced DNA damage, and reversed inflammatory signaling pathways (such as NF-κB). It is being investigated as a microbiome-based strategy for the prevention and treatment of ETBF-associated infections and colorectal cancer.
02
Targets
BFT (Bacteroides fragilis toxin)
Beyond the preview
Go deeper on Bac-FRP-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bac-FRP-3.